Pharmacotherapeutics of Ocular Infections

Abstract

Get full access to this article

View all access options for this article.

References

Gourley DR : Ophthalmic products, in Feldmann EG , Blockstein WL (eds): Handbook of Nonprescription Drugs (ed 9). Washington, DC , American Pharmaceutical Association, 1990, p 582

Robinson JR (ed): Ophthalmic Drug Delivery Systems. Washington, DC, American Pharmaceutical Association, 1980

Fraunfelder FT : Extraocular fluid dynamics: How best to apply topical ocular medications. Trans Am Ophthalmol Soc 74:457, 1976

Tabbara KF , Hyndiuk RA (eds): Infections of the Eye. Boston, MA, Little, Brown, 1986

Walsh JB , Gold A , Charles H (eds): 1990 Physician's Desk Reference for Ophthalmology (ed 18). Oradell, NJ, Medical Economics Company Inc 1990

Ophthalmology Pocket Reference (ed 3). Irvine, CA, Allergan Pharmaceuticals Publication, 1990

Lamberts DW , Potter DE (eds): Clinical Ophthalmic Pharmacology. Boston, MA, Little, Brown, 1987

Lesar TS , Fiscella RG : Antimicrobial drug delivery to the eye. Drug Intell Clin Pharm 19:642-654, 1985

Fiscella RG , Biggio CA , O'Dea PR : Ophthalmic infections, in Pharmacotherapy: A Pathophysiologic Approach. New York, NY, Elsevier Science, 1989, pp 1106-1121

10.

Bowe BE , Snyder JW , Elferman RA : An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations. Am J Ophthalmol 111:686-689, 1991

11.

McBride HA , Martinez DR , Trang JM , et al: Stability of gentamicin sulfate and tobramycin sulfate in extemporaneously prepared ophthalmic solutions at 8°C. Am J Hosp Pharm 48:507-509, 1991

12.

Ormerod LD , Heseltine Pnr , Alfonso E. , et al: Gentamicin-resistant pseudomonal infection. Cornea 8:195-199, 1989

13.

Barza M. , Baum J. , Kane A. : Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. Am J Ophthalmol 83:407, 1977

14.

Phillips I. : Good antimicrobial prescribing: Aminoglycosides . Lancet 2:311,1982

15.

Barza M. : Antibacterial agents in the treatment of ocular infections. Infect Dis Clin North Am 3:533-551, 1989

16.

Abrams SM , Degnan TJ , Vinciguerra V. : Marrow aplasia following topical application of chloramphenicol eye ointment . Arch Intern Med 140:576-577, 1980

17.

Rosenthal RL , Blackman A. : Bone marrow hypoplasia following use of chloramphenicol eyedrops. JAMA 191:136-137,1965

18.

Fraunfelder FT , Bagby GC , Kelly DJ : Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 93:356-360, 1982

19.

Alcon Ophthalmic : Packaging information for Ciloxan™ ophthalmic solution. Alcon Laboratories, Inc, Fort Worth, TX, December 1990

20.

Thompson GA : Pharmacy and therapeutics committee decisions . County Los Angeles Dept Health Serv Drug Bull 16:1, 1991

21.

Schluter G. : Ciprofloxacin. Review of potential toxicologic effects. Am J Med 82:91, 1987

22.

Merck Sharp & Dohme : Packaging information for Chibroxin™ ophthalmic solution. Merck Sharp & Dohme, Division of Merck & Co, Inc, West Point, PA, June 1991

23.

Borrmann LR , Leopold IH : The potential use of quinolones in future ocular antimicrobial therapy. Am J Ophthalmol 106:227-229, 1988

24.

Zun LS , Mathews J. : Formulary of commonly used ophthalmologic medications. Emery Med Clin North Am 6:121-126,1988

25.

Havener WH : Ocular Pharmacology (ed 5). St Louis, MO, Mosby, 1983

26.

Montgomerie JZ , Edwards JE , Guze LB : Synergism of amphotericin B and 5-fluorocytosine for Candida species. J Infect Dis 132:82, 1975

27.

Pappagianis D. , Collins MS , Hector R. , et al: Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 16:123, 1979

28.

Wilhelmus KR , Coster DJ , Jones BR : Acyclovir and debridement in the treatment of ulcerative kerpetic keratitis. Am J Ophthalmol 91:323, 1981

29.

Kaufman H. , Nesburn AB , Maloney ED : IDU therapy of herpes simplex. Arch Ophthalmol 67:583, 1962

30.

Berson FG (ed): Ophthalmology Study Guide For Students and Practitioners of Medicine (ed 5). San Francisco, CA, American Academy of Ophthalmology, 1987

31.

Rubin B. , Palestine AG : Complications of corticosteroid and immunosuppressive drugs. Int Ophthalmol Clin 29:159-171, 1989

32.

Bailey WR , Scott EG : Diagnostic Microbiology (ed 4). St. Louis, MO, Mosby, 1974

33.

Vaughan D. , Asbury T. , Tabbara KF : 1989 General Ophthalmology (ed 12). Norwalk, CT, Lange, 1989

34.

Tasman W , Jaeger EA (eds): Duane's Clinical Ophthalmology, vols 1-5 (revised ed). Philadelphia, PA, Lippincott, 1990

35.

Stehr-Green JK , Bailey TM , Visvesvara GS : The epidemiology of acanthamoeba keratitis in the United States. Am J Ophthalmol 107:331-356, 1989

36.

May & Baker Pharmaceuticals : Packaging information for Brolene™ drops. May & Baker Ltd, Rhone-Poulenc Group, Dagenham, England

37.

May & Baker Pharmaceuticals. Packaging information for Brolene™ ointment. May & Baker Ltd, Phone-Poulenc Group, Dagenham, England

38.

Berger ST , Mondino BJ , Hoft RH , et al: Successful medical management of acanthamoeba keratitis. Am J Ophthalmol 110:395-403, 1990

39.

Tarantino N. , Anger CB , Nelson NE : Acanthamoeba keratitis and contact lens wear: A review of the literature. Contact Lens Spectrum, January 1988

40.

Mills J. , Jacobson MA , O'Donnell JJ , et al: Treatment of cytomegalovirus retinitis in patients with AIDS . Rev Infect Dis 10: 5522-531, 1988 (suppl 3)

41.

Palestine AG Clinical aspects of cytomegalovirus retinitis . Rev Infect Dis 10: S515-S21, 1988 (suppl 3)

42.

Ashton P. (U of Kentucky): Sustained release device for the intraocular delivery of ganciclovir. Guest lecture presented at the Estelle Doheny Eye Institute, Los Angeles, CA

1990

43.

Starr C. : Syntex laboratories sets its sights on CMV retinitis. Drug Topics, November 1990

44.

Srinevasan BD (ed): Ocular Therapeutics. New York, NY, Masson , 1980